Topoisomerase IIa gene amplification predicts favorable outcome of tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2 positive breast cancer. Results from the randomized trial SBG 9401.
Research output: Contribution to journal › Published meeting abstract
Standard
Topoisomerase IIa gene amplification predicts favorable outcome of tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2 positive breast cancer. Results from the randomized trial SBG 9401. / Tanner, MM; Isola, JJ; Wiklund, T; Erikstein, B; Kellokumpu-Lehtinen, P; Malmström, Per; Wilking, N; Nilsson, J; Bergh, J.
In: Journal of Clinical Oncology, Vol. 23, No. 16S, 2005, p. 841S-841S.Research output: Contribution to journal › Published meeting abstract
Harvard
APA
CBE
MLA
Vancouver
Author
RIS
TY - JOUR
T1 - Topoisomerase IIa gene amplification predicts favorable outcome of tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2 positive breast cancer. Results from the randomized trial SBG 9401.
AU - Tanner, MM
AU - Isola, JJ
AU - Wiklund, T
AU - Erikstein, B
AU - Kellokumpu-Lehtinen, P
AU - Malmström, Per
AU - Wilking, N
AU - Nilsson, J
AU - Bergh, J
PY - 2005
Y1 - 2005
M3 - Published meeting abstract
VL - 23
SP - 841S-841S
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
SN - 0732-183X
IS - 16S
T2 - 2005 ASCO Annual Meeting
Y2 - 2 January 0001
ER -